FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and...
(PRWeb July 20, 2012)
Read the full story at http://www.prweb.com/releases/2012/7/prweb9719272.htm